Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc.
1900 Powell St, Ste 1000,
Emeryville, CA 94608
Phone: (510) 450-3500Website: https://www.adamaspharma.com/Careers: www.adamaspharma.com/careers
Latest news
- Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
1 February 2021 - FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
24 August 2017 - Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
12 June 2017 - Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
6 January 2017 - Adamas Submits New Drug Application to U.S. FDA for ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
27 October 2016
Drugs Associated with Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Gocovri
Generic name: amantadine Drug class: dopaminergic antiparkinsonism agents |
1 review | 8.0 / 10 |
|
Namzaric
Generic name: donepezil/memantine Drug class: cholinesterase inhibitors |
6 reviews | 8.8 / 10 |
|
Osmolex ER
Generic name: amantadine Drug class: dopaminergic antiparkinsonism agents |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
